Both PRP and LDRT are non-surgical osteoarthritis options that sit outside standard first-line care, and both are frequently not covered by insurance. The PRP evidence is genuinely mixed — this page presents that honestly.
ACR/AF 2019: Strongly recommended against PRP for osteoarthritis. Rationale: preparation heterogeneity (no standardized product) makes pooling evidence difficult to interpret; available evidence insufficient to conclude benefit. OARSI 2019: Level 5, strongly not recommended. AAOS: Limited recommendation — "may reduce pain and improve function" — weakly in favor, not against; this differs from ACR/OARSI. NICE: IPG637 special arrangements only — institutional governance required.
PRP's published trial volume — approximately 40 trials, 3,035 patients — exceeds LDRT's approximately 12 studies. That volume has not resolved the heterogeneity concern. The concern ACR raises is not the quantity of evidence but its interpretability: varying preparations, concentrations, and activation states make pooled results difficult to interpret. Some meta-analyses report benefit over corticosteroids or HA at 6–12 months; benefit sizes in sham-controlled RCTs are typically smaller than uncontrolled series suggested.
LDRT randomized evidence divides by dose protocol. Modern protocol (≤0.5 Gy/fraction): LoRD-KNeA 2025 (70% vs 42% sham, p = 0.014), Fazilat-Panah 2025 (all outcomes p < 0.01), Makarova et al. (0.45 Gy/fraction; disability 9.5% vs 17.8%; arthroplasty 67% risk reduction; same background therapy both arms), ArthroRad 2024 (dose comparison; LoRD-KNeA confirms both arms active). Older protocol (1 Gy/fraction): Mahler 2018, Minten 2018 — null. 2026 ARS AUC: 60–90% overall response. Every LDRT treatment delivers a measurable dose in gray to a defined target volume — LDRT is a standardized treatment, which is the specific contrast ACR draws with PRP's preparation heterogeneity.
PRP is rarely covered by insurance for osteoarthritis — most payers including Medicare classify it as experimental. Out-of-pocket: approximately $500–$2,500+ per injection; most protocols 2–3 injections. LDRT coverage is variable; multiple treating centers report Medicare and commercial plan coverage where PRP has none.
PRP may be reasonable for patients who prefer autologous biologics, have earlier-stage OA, or have not tried PRP. LDRT may be more appropriate for chronic refractory OA after prior injections including PRP, for patients who prefer non-injection treatment, or where LDRT coverage is available where PRP is not.
Related: All comparisons | LDRT vs. HA injections | Cost and coverage
Medically reviewed by: Robert Warren Floyd, M.D., Ph.D. — Resident Physician, Radiation Oncology, The University of Texas MD Anderson Cancer Center. Last reviewed: August 2, 2026. Independent personal project — not affiliated with or endorsed by MD Anderson Cancer Center. Funding & independence disclosure.